Home
/
Treatment
/
[α⿿N-(2⿿succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[ε⿿N-(2⿿succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[ε⿿N-(2⿿succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr

[α⿿N-(2⿿succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[ε⿿N-(2⿿succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[ε⿿N-(2⿿succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr

	[α⿿N-(2⿿succinyl-paclitaxel)Thr]-Phe-Phe-Tyr-Gly-Gly-Ser-Arg-Gly-[ε⿿N-(2⿿succinyl-paclitaxel)Lys]-Arg-Asn-Asn-Phe-[ε⿿N-(2⿿succinyl-paclitaxel)Lys]-Thr-Glu-Glu-Tyr
Trade Name
Orphan Indication	Breast cancer patients with brain metastases
USA Market Approval	USA
USA Designation Date	2015-04-15 00:00:00
Sponsor	Angiochem, Inc.;201 President Kennedy, Montreal, Quebec H2X 3Y7;